Mark M. Jones

发表

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

James R. Anderson, R. Dummer, J. Larkin, 2019, The Lancet. Oncology.

The Chinese herbal formulation biminne in management of perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12-week clinical trial.

V. Gebski, Mark M. Jones, G. Hu, 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

M. Griesshammer, S. Verstovsek, R. Mesa, 2016, European journal of haematology.

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

H. Kantarjian, F. Ravandi, X. Thomas, 2014, BMC Cancer.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

M. Griesshammer, S. Verstovsek, R. Mesa, 2015, The New England journal of medicine.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

M. Cazzola, M. Griesshammer, S. Verstovsek, 2016, Haematologica.

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

J. Spano, Mark M. Jones, J. Bowman, 2022, Frontiers in Oncology.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

J. Dipersio, M. Arcasoy, H. Kantarjian, 2017, Journal of Hematology & Oncology.

A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.

H. Kantarjian, X. Thomas, J. Delaunay, 2014, Clinical lymphoma, myeloma & leukemia.

Association between Treatment Response and Potential Indicators of Efficacy and Safety in a Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia

M. Minden, H. Kantarjian, Mark M. Jones, 2015 .

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, Annals of Hematology.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

M. Griesshammer, S. Verstovsek, P. Guglielmelli, 2018, British journal of haematology.

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

J. Byrne, S. Verstovsek, R. Mesa, 2014, British journal of haematology.

First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

E. Healy, R. Allen, Mark M. Jones, 2017, European Journal of Clinical Pharmacology.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

E. Schmidt, A. Balmanoukian, S. Patel, 2017 .

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

H. Kantarjian, X. Thomas, J. Delaunay, 2015, Journal of blood medicine.

Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

H. Kantarjian, X. Thomas, J. Delaunay, 2012 .

A Post Hoc Landmark Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

H. Kantarjian, X. Thomas, J. Delaunay, 2012 .

H. Kantarjian, F. Ravandi, X. Thomas, 2014, BMC Cancer.

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

T. Barbui, L. Knoops, A. Vannucchi, 2015 .

Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial

M. Griesshammer, S. Verstovsek, R. Mesa, 2014 .

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia☆☆☆

M. Minden, H. Kantarjian, J. Delaunay, 2013, Leukemia research reports.

Does the frequency of cancer as the etiology for hypercalcemia differ between hospitalized populations and outpatient primary care populations?

Mark M. Jones, Supriya Gupta, P. Bhandari, 2020 .

Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, V. Borges, 2017 .

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

T. Barbui, L. Knoops, A. Vannucchi, 2016, Leukemia.

Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial.

M. Griesshammer, S. Verstovsek, M. Hino, 2015 .